| ²é¿´: 788 | »Ø¸´: 4 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
·ãÒÀŵгæ (СÓÐÃûÆø)
|
[ÇóÖú]
ѪҺ²¡ ÒÑÓÐ1È˲ÎÓë
|
|
|
AGS67E bound to >80% of NHL and T-cell lymphomas, 100% of CLL and 100% of AML patient-derived samples, including CD34+CD38- leukemic stem cells.ÇëÎÊÄÄλ֪µÀÕâ¸ö bound toÊÇʲôÒâË¼ÄØ£¬¡£¡£ Anti-CD37 Monomethyl Auristatin E Antibody Drug Conjugate»¹ÓÐÕâ¾ä»°¡£¡£¡£ It is a fully human monoclonal IgG2 antibody (AGS67C) conjugated»¹ÓÐÕâ¾ä¡£¡£¡£ Çó´óÉñ°ïÖú¡£¡£¡£¡£ |
» ²ÂÄãϲ»¶
AIE¹âÃô¼Á-°×µÆ¹¦ÂÊÃܶȵļÆËã
ÒѾÓÐ1È˻ظ´
ҽѧѧ˶Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¼±ÖØÖ¢Ò½Ñ§/´´ÉË/ÉÕÉË/ÕûÐÎÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ79È˻ظ´
ÌåÍâÕï¶ÏÊÔ¼Á
ÒѾÓÐ0È˻ظ´
324Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
º¼ÖÝʦ·¶´óѧ»ù´¡Ò½Ñ§ÔºÃâÒßÓ벡ÔÉúÎïѧϵ-Áõ¹ãÓî¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
º¼ÖÝʦ·¶´óѧ»ù´¡Ò½Ñ§ÔºÑо¿Éúµ÷¼ÁÕÐÉú»ðÈÈÀ´Ï®
ÒѾÓÐ0È˻ظ´
0860ÉúÎïÒ½Ò©/1053¹«¹²ÎÀÉú-ÏÃÃÅ´óѧÉٸɼƻ®×¨Ë¶µ÷¼Á£»ÁíÓзÇÈ«ÈÕÖÆ¹«ÎÀר˶Ãû¶îµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÏÃÃÅ´óѧ¹ú¼ÒÖØµãʵÑéÊÒ²¡Ô΢ÉúÎïÓ뿹¸ÐȾÖÎÁÆ¿ÎÌâ×é2026½ì²©Ê¿ÕÐÉú
ÒѾÓÐ0È˻ظ´

³ÂÕÂÆ½
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1826.3
- ºì»¨: 2
- Ìû×Ó: 1441
- ÔÚÏß: 127.1Сʱ
- ³æºÅ: 3369500
- ×¢²á: 2014-08-17
- ÐÔ±ð: GG
- רҵ: °×Ѫ²¡
5Â¥2017-04-01 11:55:34
SuperAA
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 37
- Ìû×Ó: 11
- ÔÚÏß: 3.7Сʱ
- ³æºÅ: 3868452
- ×¢²á: 2015-05-14
- רҵ: °×Ѫ²¡
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
Anti-CD37 Monomethyl Auristatin E Antibody Drug Conjugate Õâ¸öÊÇ¿¹ÌåżÁªÒ©Î Monomethyl Auristatin E £¨MMAE£©ÊǺ£Íö¾ËصÄÒ»ÖÖ£¬Ò²¾ÍÊÇ˵°ÑCD37-Á´½ÓÓëMMAE.Ò²¾ÍÊǰÐÏòÒ©ÎĿǰºÜ»ð£¬µ«ÌرðÉÕÇ®¡£¡£¡£¡£¡£¡£ |
2Â¥2015-08-10 11:15:59
SuperAA
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 37
- Ìû×Ó: 11
- ÔÚÏß: 3.7Сʱ
- ³æºÅ: 3868452
- ×¢²á: 2015-05-14
- רҵ: °×Ѫ²¡
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
·ãÒÀŵ: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл£¬Ð»Ð» 2016-01-12 20:30:09
·ãÒÀŵ: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл£¬Ð»Ð» 2016-01-12 20:30:09
| bound to ½áºÏÓÚXXXX£¬ÀýÈçMMAE½áºÏÓÚ¿¹ÌåµÄCysµÈ |
3Â¥2015-08-10 11:17:04
³ÂÕÂÆ½
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1826.3
- ºì»¨: 2
- Ìû×Ó: 1441
- ÔÚÏß: 127.1Сʱ
- ³æºÅ: 3369500
- ×¢²á: 2014-08-17
- ÐÔ±ð: GG
- רҵ: °×Ѫ²¡
4Â¥2017-04-01 11:52:00













»Ø¸´´ËÂ¥